CNSX:CURE - Biocure Technology Stock Price, News, & Analysis

0.00 (0.00 %)
(As of 07/19/2019 04:00 PM ET)
Today's Range
Now: $0.30
50-Day Range
MA: $0.33
52-Week Range N/A
Volume10,000 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
Biocure Technology Inc. develops and commercializes biosimilar pharmaceutical products in South Korea. The company is developing Interferon Beta 1b for the treatment of multiple sclerosis; Ranibizumab, a monoclonal antibody fragment for the treatment of macular degeneration, as well as to treat a type of eye problem known as macular edema; and Filgrastim to treat neutropenia, a lack of white blood cells caused by cancer, bone marrow transplant, chemotherapy, or by other conditions. It is also developing a foot and mouth disease vaccine, a hair growth production product, and a breast cancer detection kit. Biocure Technology Inc. is headquartered in Vancouver, Canada.

Industry, Sector and Symbol

Industry Biotechnology



Sales & Book Value

Annual SalesN/A



Next Earnings DateN/A

Receive CURE News and Ratings via Email

Sign-up to receive the latest news and ratings for CURE and its competitors with MarketBeat's FREE daily newsletter.

Biocure Technology (CNSX:CURE) Frequently Asked Questions

What is Biocure Technology's stock symbol?

Biocure Technology trades on the CNSX under the ticker symbol "CURE."

Has Biocure Technology been receiving favorable news coverage?

Press coverage about CURE stock has been trending somewhat positive recently, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Biocure Technology earned a news sentiment score of 2.0 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for Biocure Technology.

Who are some of Biocure Technology's key competitors?

What other stocks do shareholders of Biocure Technology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Biocure Technology investors own include Zynerba Pharmaceuticals (ZYNE), Eiger Biopharmaceuticals (EIGR), Heron Therapeutics (HRTX), Motus GI (MOTS), Synthorx (THOR), Vuzix (VUZI), Blackstone Mortgage Trust (BXMT), Moderna Inc (NASDAQ) (MRNA), Protech Home Medical (PHM) and Lexagene (LXG).

Who are Biocure Technology's key executives?

Biocure Technology's management team includes the folowing people:
  • Dr. Sang Mok Lee Ph.D., Pres, CEO & Director (Age 53)
  • Mr. Konstatin Lichtenwald, CFO & Director
  • Mr. Marco Nonni, Consultant

How do I buy shares of Biocure Technology?

Shares of CURE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Biocure Technology's stock price today?

One share of CURE stock can currently be purchased for approximately $0.30.

What is Biocure Technology's official website?

The official website for Biocure Technology is

How can I contact Biocure Technology?

The company can be reached via phone at 604-609-7149.

MarketBeat Community Rating for Biocure Technology (CNSX CURE)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  15 (Vote Outperform)
Underperform Votes:  16 (Vote Underperform)
Total Votes:  31
MarketBeat's community ratings are surveys of what our community members think about Biocure Technology and other stocks. Vote "Outperform" if you believe CURE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CURE will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/19/2019 by Staff

Featured Article: Oversold

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel